Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy

被引：312

作者：

Nishino, Mizuki ^{[1
]}

Sholl, Lynette M. ^{[1
]}

Hodi, F. Stephen ^{[1
]}

机构：

[1] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 373卷 / 03期

关键词：

ADVANCED MELANOMA; SAFETY; NIVOLUMAB; TRIAL;

D O I：

10.1056/NEJMc1505197

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：288 / 290

页数：3

共 5 条

[1] European Respiratory Society, 2002, Am J Respir Crit Care Med, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]
[2] Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Rizvi, Naiyer A.
Mazieres, Julien
Planchard, David
Stinchcombe, Thomas E.
Dy, Grace K.
Antonia, Scott J.
Horn, Leora
Lena, Herve
Minenza, Elisa
Mennecier, Bertrand
Otterson, Gregory A.
Campos, Luis T.
Gandara, David R.
Levy, Benjamin P.
Nair, Suresh G.
Zalcman, Gerard
Wolf, Juergen
Souquet, Pierre-Jean
Baldini, Editta
Cappuzzo, Federico
Chouaid, Christos
Dowlati, Afshin
Sanborn, Rachel
Lopez-Chavez, Ariel
Grohe, Christian
Huber, Rudolf M.
Harbison, Christopher T.
Baudelet, Christine
Lestini, Brian J.
Ramalingam, Suresh S.
[J]. LANCET ONCOLOGY, 2015, 16 (03) : 257 - 265
[3] Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Robert, Caroline
Ribas, Antoni
Wolchok, Jedd D.
Hodi, F. Stephen
Hamid, Omid
Kefford, Richard
Weber, Jeffrey S.
Joshua, Anthony M.
Hwu, Wen-Jen
Gangadhar, Tara C.
Patnaik, Amita
Dronca, Roxana
Zarour, Hassane
Joseph, Richard W.
Boasberg, Peter
Chmielowski, Bartosz
Mateus, Christine
Postow, Michael A.
Gergich, Kevin
Elassaiss-Schaap, Jeroen
Li, Xiaoyun Nicole
Iannone, Robert
Ebbinghaus, Scot W.
Kang, S. Peter
Daud, Adil
[J]. LANCET, 2014, 384 (9948) : 1109 - 1117
[4] Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Topalian, Suzanne L.
Sznol, Mario
McDermott, David F.
Kluger, Harriet M.
Carvajal, Richard D.
Sharfman, William H.
Brahmer, Julie R.
Lawrence, Donald P.
Atkins, Michael B.
Powderly, John D.
Leming, Philip D.
Lipson, Evan J.
Puzanov, Igor
Smith, David C.
Taube, Janis M.
Wigginton, Jon M.
Kollia, Georgia D.
Gupta, Ashok
Pardoll, Drew M.
Sosman, Jeffrey A.
Hodi, F. Stephen
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1020 - +
[5] Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Topalian, Suzanne L.
Hodi, F. Stephen
Brahmer, Julie R.
Gettinger, Scott N.
Smith, David C.
McDermott, David F.
Powderly, John D.
Carvajal, Richard D.
Sosman, Jeffrey A.
Atkins, Michael B.
Leming, Philip D.
Spigel, David R.
Antonia, Scott J.
Horn, Leora
Drake, Charles G.
Pardoll, Drew M.
Chen, Lieping
Sharfman, William H.
Anders, Robert A.
Taube, Janis M.
McMiller, Tracee L.
Xu, Haiying
Korman, Alan J.
Jure-Kunkel, Maria
Agrawal, Shruti
McDonald, Daniel
Kollia, Georgia D.
Gupta, Ashok
Wigginton, Jon M.
Sznol, Mario
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2443 - 2454

← 1 →